GSK/Shire Vyvanse deal fuels speculation
The UK's Shire has entered a co-promotion agreement with drug major GlaxoSmithKline for Vyvanse (lisdexamfetamine dimesylate) in the treatment of attention-deficit hyperactivity disorder in adults. The firm's share price rose 8% on the day of the news, March 31, fueled by speculation that the move was a prelude to a takeover by the UK firm.
This three-year agreement covers the USA and will more than double the reach and frequency of the current sales effort for Vyvanse by adding over 600 sales representatives from GSK. The sales force is expected to begin promoting Vyvanse to physicians in May. The agreement is based on profit-sharing above an agreed-upon baseline figure.
Vyvanse was introduced in the USA in 2007 for the treatment of ADHD in children aged six to 12 years and approved in April 2008 in adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze